SP
ACHL

Syncona Portfolio’s Achilles Therapeutics ACHL Stock Holding History

Syncona Portfolio’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,086,909
Closed -$12.6M – 3
2024
Q4 		$12.6M Hold
11,086,909
– – 23.86% 2
2024
Q3 		$11.3M Hold
11,086,909
– – 14.01% 2
2024
Q2 		$9.04M Hold
11,086,909
– – 10.52% 2
2024
Q1 		$13.9M Hold
11,086,909
– – 9.24% 2
2023
Q4 		$9.86M Hold
11,086,909
– – 6.25% 2
2023
Q3 		$10.1M Hold
11,086,909
– – 15.03% 2
2023
Q2 		$10.5M Hold
11,086,909
– – 15.8% 2
2023
Q1 		$10.6M Hold
11,086,909
– – 17.26% 2
2022
Q4 		$9.98M Hold
11,086,909
– – 15.84% 3
2022
Q3 		$25.1M Hold
11,086,909
– – 43.54% 1
2022
Q2 		$27.9M Hold
11,086,909
– – 39.7% 1
2022
Q1 		$55.5M Hold
11,086,909
– – 53.06% 1
2021
Q4 		$55.5M Buy
+11,086,909
New +$67.1M 53.06% 1

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Syncona Portfolio's ACHL Position: Q1 2025 in Review

Syncona Portfolio sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 11,086,909 shares — an estimated $12.6M sold.

Syncona Portfolio first reported a position in ACHL in Q4 2021 and held it in 13 quarters. The position peaked at $55.5M in Q1 2022. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Syncona Portfolio reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Syncona Portfolio sold 11,086,909 Achilles Therapeutics shares in Q1 2025, an estimated $12.6M.
  • Syncona Portfolio first reported a position in Achilles Therapeutics in Q4 2021 and held it in 13 quarters.
  • Syncona Portfolio's Achilles Therapeutics position peaked at $55.5M in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Syncona Portfolio's 13F filing for Q1 2025, filed 7 May 2025.